- Home
- OMCL vs MIRM Comparison
OMCL vs MIRM Comparison
Compare OMCL & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OMCL | MIRM |
|---|---|---|
| Founded | 1992 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 5.7B |
| IPO Year | 2000 | 2019 |
Fundamental Metrics
Financial Performance| Metric | OMCL | MIRM |
|---|---|---|
| Price | $44.53 | $99.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $55.83 | ★ $119.85 |
| AVG Volume (30 Days) | 619.6K | ★ 916.0K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $787,309,000.00 | $19,138,000.00 |
| Revenue This Year | $6.77 | $26.22 |
| Revenue Next Year | $5.22 | $22.04 |
| P/E Ratio | $171.98 | ★ N/A |
| Revenue Growth | ★ 9.93 | N/A |
| 52 Week Low | $26.85 | $42.89 |
| 52 Week High | $51.84 | $114.99 |
Technical Indicators
Market Signals| Indicator | OMCL | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 62.70 | 46.58 |
| Support Level | $43.34 | $97.49 |
| Resistance Level | $46.11 | $107.51 |
| Average True Range (ATR) | 1.85 | 6.76 |
| MACD | -0.03 | -0.23 |
| Stochastic Oscillator | 58.47 | 36.93 |
Price Performance
Historical ComparisonAbout OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.